Esperion Therapeutics Inc. Insider Trading

ESPR

Last 12 months

Insiders sold 576K and bought nothing on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. The last open-market buy by an executive or director was in May 2023.

Net open-market

−576K

0 buys · 10 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

0 / 3

executives and directors

Last open-market buy

May 2023

May 11, 2023

Get an email when ESPR's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Jun 17	Benjamin Looker Chief Legal Officer	SoldNo plan	11,824	$3.16	37K	1.7%	Form 4
Jun 17	Sheldon L. Koenig President and CEO	SoldNo plan	53,588	$3.16	169K	2.5%	Form 4
Jun 17	Benjamin Halladay Chief Financial Officer	SoldNo plan	10,773	$3.16	34K	1.5%	Form 4
Mar 17	Benjamin Looker Chief Legal Officer	SoldNo plan	5,708	$2.70	15K	0.8%	Form 4
Mar 17	Sheldon L. Koenig President and CEO	SoldNo plan	25,578	$2.72	70K	1.2%	Form 4
Mar 17	Benjamin Halladay Chief Financial Officer	SoldNo plan	6,424	$2.71	17K	0.9%	Form 4
Jan 20	Benjamin Looker General Counsel	SoldNo plan	1,689	$2.88	5K	0.4%	Form 4
Dec 17, 2025	Sheldon L. Koenig President and CEO	SoldNo plan	48,244	$3.67	177K	3.2%	Form 4
Dec 17, 2025	Benjamin Halladay Chief Financial Officer	SoldNo plan	7,337	$3.67	27K	1.5%	Form 4
Dec 17, 2025	Benjamin Looker General Counsel	SoldNo plan	6,517	$3.67	24K	1.7%	Form 4
Oct 17, 2025	Benjamin Looker General Counsel	SoldNo plan	1,248	$2.62	3K	0.3%	Form 4
Sep 17, 2025	Benjamin Halladay Chief Financial Officer	SoldNo plan	7,046	$2.81	20K	1.5%	Form 4
Sep 17, 2025	Benjamin Looker General Counsel	SoldNo plan	6,267	$2.80	18K	1.6%	Form 4
Sep 17, 2025	Sheldon L. Koenig President and CEO	SoldNo plan	28,427	$2.79	79K	1.8%	Form 4
Jul 17, 2025	Benjamin Looker General Counsel	SoldNo plan	1,304	$1.13	1K	0.3%	Form 4
Jul 17, 2025	Benjamin Halladay Chief Financial Officer	SoldNo plan	11	$1.12	$12	<0.1%	Form 4
Jun 17, 2025	Benjamin Looker General Counsel	SoldNo plan	6,422	$1.15	7K	1.6%	Form 4
Jun 17, 2025	Sheldon L. Koenig President and CEO	SoldNo plan	30,474	$1.11	34K	1.9%	Form 4
Jun 17, 2025	Benjamin Halladay Chief Financial Officer	SoldNo plan	7,229	$1.15	8K	1.5%	Form 4
Apr 17, 2025	Eric Warren Chief Commercial Officer	SoldNo plan	108	$0.98	$106	<0.1%	Form 4
Apr 17, 2025	Benjamin Halladay Chief Financial Officer	SoldNo plan	8	$0.96	$8	<0.1%	Form 4
Mar 18, 2025	Benjamin Halladay Chief Financial Officer	SoldNo plan	3,535	$1.48	5K	0.7%	Form 4
Mar 18, 2025	Eric Warren Chief Commercial Officer	SoldNo plan	2,433	$1.49	4K	0.7%	Form 4
Mar 18, 2025	Sheldon L. Koenig President and CEO	SoldNo plan	13,047	$1.50	20K	0.8%	Form 4
Feb 19, 2025	Eric Warren Chief Commercial Officer	SoldNo plan	239	$1.87	$447	0.1%	Form 4
Feb 19, 2025	Benjamin Halladay Chief Financial Officer	SoldNo plan	11	$1.86	$20	<0.1%	Form 4
Jan 17, 2025	Benjamin Halladay Chief Financial Officer	SoldNo plan	9	$2.27	$20	<0.1%	Form 4
Jan 17, 2025	Eric Warren Chief Commercial Officer	SoldNo plan	123	$2.26	$278	<0.1%	Form 4
Dec 17, 2024	Benjamin Halladay Chief Financial Officer	SoldNo plan	3,245	$2.42	8K	1.3%	Form 4
Dec 17, 2024	Eric Warren Chief Commercial Officer	SoldNo plan	2,234	$2.43	5K	1.4%	Form 4
Dec 17, 2024	Sheldon L. Koenig President and CEO	SoldNo plan	12,447	$2.47	31K	1.7%	Form 4
Nov 19, 2024	Eric Warren Chief Commercial Officer	SoldNo plan	197	$2.17	$427	0.1%	Form 4

Jun 17No plan
Benjamin Looker
Chief Legal Officer · sold 11,824 at $3.16
37K
1.7% of stake
Jun 17No plan
Sheldon L. Koenig
President and CEO · sold 53,588 at $3.16
169K
2.5% of stake
Jun 17No plan
Benjamin Halladay
Chief Financial Officer · sold 10,773 at $3.16
34K
1.5% of stake
Mar 17No plan
Benjamin Looker
Chief Legal Officer · sold 5,708 at $2.70
15K
0.8% of stake
Mar 17No plan
Sheldon L. Koenig
President and CEO · sold 25,578 at $2.72
70K
1.2% of stake
Mar 17No plan
Benjamin Halladay
Chief Financial Officer · sold 6,424 at $2.71
17K
0.9% of stake
Jan 20No plan
Benjamin Looker
General Counsel · sold 1,689 at $2.88
5K
0.4% of stake
Dec 17, 2025No plan
Sheldon L. Koenig
President and CEO · sold 48,244 at $3.67
177K
3.2% of stake
Dec 17, 2025No plan
Benjamin Halladay
Chief Financial Officer · sold 7,337 at $3.67
27K
1.5% of stake
Dec 17, 2025No plan
Benjamin Looker
General Counsel · sold 6,517 at $3.67
24K
1.7% of stake
Oct 17, 2025No plan
Benjamin Looker
General Counsel · sold 1,248 at $2.62
3K
0.3% of stake
Sep 17, 2025No plan
Benjamin Halladay
Chief Financial Officer · sold 7,046 at $2.81
20K
1.5% of stake
Sep 17, 2025No plan
Benjamin Looker
General Counsel · sold 6,267 at $2.80
18K
1.6% of stake
Sep 17, 2025No plan
Sheldon L. Koenig
President and CEO · sold 28,427 at $2.79
79K
1.8% of stake
Jul 17, 2025No plan
Benjamin Looker
General Counsel · sold 1,304 at $1.13
1K
0.3% of stake
Jul 17, 2025No plan
Benjamin Halladay
Chief Financial Officer · sold 11 at $1.12
$12
<0.1% of stake
Jun 17, 2025No plan
Benjamin Looker
General Counsel · sold 6,422 at $1.15
7K
1.6% of stake
Jun 17, 2025No plan
Sheldon L. Koenig
President and CEO · sold 30,474 at $1.11
34K
1.9% of stake
Jun 17, 2025No plan
Benjamin Halladay
Chief Financial Officer · sold 7,229 at $1.15
8K
1.5% of stake
Apr 17, 2025No plan
Eric Warren
Chief Commercial Officer · sold 108 at $0.98
$106
<0.1% of stake
Apr 17, 2025No plan
Benjamin Halladay
Chief Financial Officer · sold 8 at $0.96
$8
<0.1% of stake
Mar 18, 2025No plan
Benjamin Halladay
Chief Financial Officer · sold 3,535 at $1.48
5K
0.7% of stake
Mar 18, 2025No plan
Eric Warren
Chief Commercial Officer · sold 2,433 at $1.49
4K
0.7% of stake
Mar 18, 2025No plan
Sheldon L. Koenig
President and CEO · sold 13,047 at $1.50
20K
0.8% of stake
Feb 19, 2025No plan
Eric Warren
Chief Commercial Officer · sold 239 at $1.87
$447
0.1% of stake
Feb 19, 2025No plan
Benjamin Halladay
Chief Financial Officer · sold 11 at $1.86
$20
<0.1% of stake
Jan 17, 2025No plan
Benjamin Halladay
Chief Financial Officer · sold 9 at $2.27
$20
<0.1% of stake
Jan 17, 2025No plan
Eric Warren
Chief Commercial Officer · sold 123 at $2.26
$278
<0.1% of stake
Dec 17, 2024No plan
Benjamin Halladay
Chief Financial Officer · sold 3,245 at $2.42
8K
1.3% of stake
Dec 17, 2024No plan
Eric Warren
Chief Commercial Officer · sold 2,234 at $2.43
5K
1.4% of stake
Dec 17, 2024No plan
Sheldon L. Koenig
President and CEO · sold 12,447 at $2.47
31K
1.7% of stake
Nov 19, 2024No plan
Eric Warren
Chief Commercial Officer · sold 197 at $2.17
$427
0.1% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ESPR, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with ESPR

CompareIntrinsic value

INVAInnoviva Inc.

$21.26+1.58%56

MNKDMannKind Corporation

$3.93+5.36%30

IRWDIronwood Pharmaceuticals Inc.

$3.77+7.71%52

ZLABZai Lab Ltd

$22.80+3.83%40

ARDXArdelyx Inc.

$3.27+7.92%40

LQDALiquidia Corporation

$47.38+12.27%72

ORGOOrganogenesis Holdings Inc.

$0.87+4.19%50

CRMDCorMedix Inc.

$5.66+1.80%84

Held by ETFs

ESPR is in 9 US ETFs. The largest of them, with ESPR's weight in each:

Spot a number that looks wrong? Check it in ESPR's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ESPR

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.